ARS Pharmaceuticals, Inc. SPRY Cost Of Goods Sold Operating Expense
Cost Of Goods Sold Operating Expense at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept spry:CostOfGoodsSoldOperatingExpense.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s cost of goods sold operating expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s cost of goods sold operating expense?
- ARS Pharmaceuticals, Inc. (SPRY) reported cost of goods sold operating expense of $6.29M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s cost of goods sold operating expense changed year-over-year?
- ARS Pharmaceuticals, Inc.'s cost of goods sold operating expense increased by 474.6% year-over-year, from $1.09M to $6.29M.
- What does cost of goods sold operating expense mean?
- This represents the direct costs attributable to the production of goods sold by the company, including raw materials and direct labor. It serves as a primary indicator of production efficiency and gross margin potential. Monitoring this metric helps investors understand the scalability of the company's manufacturing processes.